Aspirin in Preventing Disease Recurrence in Patients With Barrett Esophagus After Successful Elimination by Radiofrequency Ablation

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

21

Participants

Timeline

Start Date

January 15, 2016

Primary Completion Date

June 18, 2019

Study Completion Date

March 17, 2026

Conditions
Barrett EsophagusEsophageal Adenocarcinoma
Interventions
DRUG

Aspirin

Given PO

OTHER

Laboratory Biomarker Analysis

Correlative studies

OTHER

Placebo Administration

Given PO

OTHER

Questionnaire Administration

Ancillary studies

Trial Locations (10)

19104

University of Pennsylvania/Abramson Cancer Center, Philadelphia

27599

UNC Lineberger Comprehensive Cancer Center, Chapel Hill

55905

Mayo Clinic in Rochester, Rochester

60611

Northwestern University, Chicago

64128

Kansas City Veterans Affairs Medical Center, Kansas City

77030

Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center, Houston

M D Anderson Cancer Center, Houston

80045

UCHealth University of Colorado Hospital, Aurora

90095

UCLA / Jonsson Comprehensive Cancer Center, Los Angeles

M5B 1W8

Saint Michael's Hospital, Toronto

All Listed Sponsors
lead

National Cancer Institute (NCI)

NIH